810 related articles for article (PubMed ID: 19654858)
1. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
Ghosn J; Chaix ML; Delaugerre C
AIDS Rev; 2009; 11(3):165-73. PubMed ID: 19654858
[TBL] [Abstract][Full Text] [Related]
2. Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure.
Vaz P; Chaix ML; Jani I; Macassa E; Bila D; Vubil A; Anderson S; Rouzioux C; Briand N; Blanche S
Pediatr Infect Dis J; 2009 Dec; 28(12):e283-7. PubMed ID: 19907359
[TBL] [Abstract][Full Text] [Related]
3. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors.
Ren J; Nichols C; Bird L; Chamberlain P; Weaver K; Short S; Stuart DI; Stammers DK
J Mol Biol; 2001 Sep; 312(4):795-805. PubMed ID: 11575933
[TBL] [Abstract][Full Text] [Related]
4. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
Domaoal RA; Demeter LM
Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
[TBL] [Abstract][Full Text] [Related]
5. The contribution of HIV fitness to the evolution pattern of reverse transcriptase inhibitor resistance.
Paintsil E; Margolis A; Collins JA; Alexander L
J Med Virol; 2006 Apr; 78(4):425-30. PubMed ID: 16482556
[TBL] [Abstract][Full Text] [Related]
6. Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors.
Saracino A; Monno L; Scudeller L; Cibelli DC; Tartaglia A; Punzi G; Torti C; Lo Caputo S; Mazzotta F; Scotto G; Carosi G; Angarano G
J Med Virol; 2006 Jan; 78(1):9-17. PubMed ID: 16299731
[TBL] [Abstract][Full Text] [Related]
7. Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents.
Adams J; Patel N; Mankaryous N; Tadros M; Miller CD
Ann Pharmacother; 2010 Jan; 44(1):157-65. PubMed ID: 19996323
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors.
Menéndez-Arias L; Betancor G; Matamoros T
Antiviral Res; 2011 Nov; 92(2):139-49. PubMed ID: 21896288
[TBL] [Abstract][Full Text] [Related]
9. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
[TBL] [Abstract][Full Text] [Related]
11. Nucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated from heavily treated adolescents in Romania.
Paraschiv S; Otelea D; Baicus C; Tinischi M; Costache M; Neaga E
Int J Infect Dis; 2009 Jan; 13(1):81-9. PubMed ID: 18632295
[TBL] [Abstract][Full Text] [Related]
12. Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre-treated HIV infected patients.
Roquebert B; Wirden M; Simon A; Deval J; Katlama C; Calvez V; Marcelin AG
J Med Virol; 2007 Mar; 79(3):207-11. PubMed ID: 17245724
[TBL] [Abstract][Full Text] [Related]
13. [Etravirine: genetic barrier and resistance development].
Llibre JM; Santos JR; Clotet B
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():32-9. PubMed ID: 20116626
[TBL] [Abstract][Full Text] [Related]
14. Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters.
Corvasce S; Violin M; Romano L; Razzolini F; Vicenti I; Galli A; Duca P; Caramma I; Balotta C; Zazzi M
Antivir Ther; 2006; 11(3):329-34. PubMed ID: 16759049
[TBL] [Abstract][Full Text] [Related]
15. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
[TBL] [Abstract][Full Text] [Related]
16. Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine.
Cahn P; Wainberg MA
J Antimicrob Chemother; 2010 Feb; 65(2):213-7. PubMed ID: 20007333
[TBL] [Abstract][Full Text] [Related]
17. [Non-nucleoside reverse transcriptase inhibitors].
Joly V; Yeni P
Ann Med Interne (Paris); 2000 Jun; 151(4):260-7. PubMed ID: 10922953
[TBL] [Abstract][Full Text] [Related]
18. Nucleotide analogue binding, catalysis and primer unblocking in the mechanisms of HIV-1 reverse transcriptase-mediated resistance to nucleoside analogues.
Selmi B; Deval J; Boretto J; Canard B
Antivir Ther; 2003 Apr; 8(2):143-54. PubMed ID: 12741627
[TBL] [Abstract][Full Text] [Related]
19. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).
de Béthune MP
Antiviral Res; 2010 Jan; 85(1):75-90. PubMed ID: 19781578
[TBL] [Abstract][Full Text] [Related]
20. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
